Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Johnson

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Journal of Cancer Metastasis and Treatment|February 1, 2021
Targeting the JAK/STAT pathway in solid tumorsZoya Qureshy, Daniel E Johnson, Jennifer R Grandis
Cancer Biology & Therapy|June 11, 2014
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitorsYan Zang, Christopher J Kirk, Daniel E Johnson
Experimental Cell Research|August 10, 2002
Potentiation of tumor necrosis factor-alpha-induced cell death by rottlerin through a cytochrome-C-independent pathwayAlakananda Basu, Daniel E Johnson, Matthew D Woolard
Seminars in Radiation Oncology|November 28, 2017
Therapeutic Implications of the Genetic Landscape of Head and Neck CancerJanice Cho, Daniel E Johnson, Jennifer R Grandis
Expert Opinion on Emerging Drugs|September 22, 2022
Emerging tyrosine kinase inhibitors for head and neck cancerZhen Long, Jennifer R Grandis, Daniel E Johnson
Nature Reviews. Clinical Oncology|February 7, 2018
Targeting the IL-6/JAK/STAT3 signalling axis in cancerDaniel E Johnson, Rachel A O'Keefe, Jennifer R Grandis
Expert Opinion on Investigational Drugs|February 13, 2019
Investigational multitargeted kinase inhibitors in development for head and neck neoplasmsAna Marija Sola, Daniel E Johnson, Jennifer R Grandis
Molecular Cancer Therapeutics|November 18, 2020
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense OligonucleotidesJamie V Shiah, Jennifer R Grandis, Daniel E Johnson
Cancer Journal (Sudbury, Mass.)|January 24, 2023
Transcription Factors and Cancer: Approaches to TargetingJamie V Shiah, Daniel E Johnson, Jennifer R Grandis
Molecular Cancer Therapeutics|December 11, 2007
Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiationMichelle B Miranda, Robert L Redner, Daniel E Johnson
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Journal of Cancer Metastasis and Treatment|February 1, 2021
Targeting the JAK/STAT pathway in solid tumorsZoya Qureshy, Daniel E Johnson, Jennifer R Grandis
Cancer Biology & Therapy|June 11, 2014
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitorsYan Zang, Christopher J Kirk, Daniel E Johnson
Experimental Cell Research|August 10, 2002
Potentiation of tumor necrosis factor-alpha-induced cell death by rottlerin through a cytochrome-C-independent pathwayAlakananda Basu, Daniel E Johnson, Matthew D Woolard
Seminars in Radiation Oncology|November 28, 2017
Therapeutic Implications of the Genetic Landscape of Head and Neck CancerJanice Cho, Daniel E Johnson, Jennifer R Grandis
Expert Opinion on Emerging Drugs|September 22, 2022
Emerging tyrosine kinase inhibitors for head and neck cancerZhen Long, Jennifer R Grandis, Daniel E Johnson
Nature Reviews. Clinical Oncology|February 7, 2018
Targeting the IL-6/JAK/STAT3 signalling axis in cancerDaniel E Johnson, Rachel A O'Keefe, Jennifer R Grandis
Expert Opinion on Investigational Drugs|February 13, 2019
Investigational multitargeted kinase inhibitors in development for head and neck neoplasmsAna Marija Sola, Daniel E Johnson, Jennifer R Grandis
Molecular Cancer Therapeutics|November 18, 2020
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense OligonucleotidesJamie V Shiah, Jennifer R Grandis, Daniel E Johnson
Cancer Journal (Sudbury, Mass.)|January 24, 2023
Transcription Factors and Cancer: Approaches to TargetingJamie V Shiah, Daniel E Johnson, Jennifer R Grandis
Molecular Cancer Therapeutics|December 11, 2007
Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiationMichelle B Miranda, Robert L Redner, Daniel E Johnson
Pageof 11